• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

FDA Revokes EUA for Autobio Diagnostics' Anti-SARS-CoV-2 Rapid Test

americanpharmaceuticalreviewAugust 13, 2020

Tag: FDA , Autobio Diagnostics , SARS-CoV-2

The U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) of the Autobio Diagnostics Co. Ltd.'s Anti-SARS-CoV-2 Rapid Tests for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human plasma from anticoagulated blood (Heparin / EDTA / sodium citrate) or serum 2 due to performance concerns with the accuracy of the test. This test may not be distributed.

Previous:Enlivex Announces First Patient Dosed in Allocetra Trial for COVID-19 with Respiratory Failure

Next:FDA Posts Additional Postmarket Information for Essure

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

FDA Revokes EUA for Autobio Diagnostics' Anti-SARS-CoV-2 Rapid Test | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

HFHA(m-6FDAP)

HFHA(m-6FDAP)
Vecuronium Bromide(FDA)

Vecuronium Bromide(FDA)
Fosphenytoin sodium (FDA)

Fosphenytoin sodium (FDA)
Thiophosphoramide (FDA)

Thiophosphoramide (FDA)
Nabumetone (FDA)

Nabumetone (FDA)
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)
Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
Deoxycyline (FDA)

Deoxycyline (FDA)
filter integrity testing fda guidelines

filter integrity testing fda guidelines
Simvastatin (FDA)

Simvastatin (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service